UMMS Affiliation

Division of Hematology and Oncology, Department of Medicine, UMass Memorial Health Care

Publication Date

2020-06-25

Document Type

Article Postprint

Disciplines

Health Services Administration | Hematology | Hemic and Lymphatic Diseases | Infectious Disease | Neoplasms | Oncology | Virus Diseases

Abstract

The outbreak of the coronavirus disease 2019 (COVID‐19) has posed an unprecedented challenge to the health care communities across the globe. As of June 17th, 2020, a total of 8,339,829 confirmed COVID-19 cases with 448,420 deaths have been reported [2]. Different parts of the world are seeing different levels of COVID-19 activity with regards to the infection rate, susceptible population, and mortality rate. The COVID-19 pandemic is a rapidly evolving emergency and is a subject of regular debate and advanced research. Patients with hematological disorders and solid malignancies have special needs and oncologists are facing a compound challenge.

Keywords

COVID-19, Cancer, Hematology, Pandemic

Rights and Permissions

This is an Accepted Manuscript of an article published in Expert Review of Hematology, posted after 12-month embargo as allowed by the publisher's author self-archiving policy at https://authorservices.taylorandfrancis.com/sharing-your-work/#.

DOI of Published Version

10.1080/17474086.2020.1787147

Source

Sahu KK, Cerny J. Managing patients with hematological malignancies during COVID-19 pandemic. Expert Rev Hematol. 2020 Jun 25. doi: 10.1080/17474086.2020.1787147. Epub ahead of print. PMID: 32580592. Link to article on publisher's site

Journal/Book/Conference Title

Expert review of hematology

Related Resources

Link to Article in PubMed

PubMed ID

32580592

Download

Share

COinS